The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects

B Salehian; J Bilas; V Mahabadi; V Aleli; K Norris; SH Bhasin

International Journal of Endocrinology and Metabolism

Research Institute for Endocrine Sciences

Current Issue All Issues In Press Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects

Author(s):

B Salehian

^1,*,

J Bilas²,

V Mahabadi²,

V Aleli²,

K Norris²,

SH Bhasin²

1Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, bsalehian@coh.org, CA, USA

2Division of Endocrinology, Metabolism and Molecular Medicine, Charles R Drew University of Medicine and Science, CA, USA

International Journal of Endocrinology and Metabolism:Vol. 6, issue 4; 162-174

Article type:Research Article

Received:Jul 16, 2008

Accepted:Nov 23, 2008

How to Cite:B SalehianJ BilasV MahabadiV AleliK NorrisSH Bhasinet al.The Effect of Pioglitazone on Adiposity, Adiponectin and Carotid Artery Intimal Thickness in Obese but Otherwise Healthy Minority Subjects.Int J Endocrinol Metab.6(4):162-174.

Abstract

We examined the hypothesis that the PPAR Gamma activator, Pioglitazone, has a fat depot specific effect and aimed at determining the ef fects of pioglitazone on changes in total and regional fat distribution, serum adiponectin levels, carotid artery intimal thickness, and subcutaneous adipose tissue histology in otherwise healthy obese men and women from a minority population.

Materials and Methods: This is a doubleblind, randomized, controlled trial, single site study of the minority population in south central Los Angeles. Thirtyfive obese, but otherwise healthy, men and women (waisttohip ratio >0.95 for men and >0.85 in women) were randomly assigned into three groups: Group A: placebo; group B, pioglitazone 30 mg/day, and group C, pioglitazone 45 mg/day, for a duration of 6 months. The primary outcome measures were changes in visceral fat as measured by Computerized Tomography scan (CT Scan) of the abdomen and thigh, body composition by Dual energy Xray Absorptiometry Scan (DXA scan) and carotid artery intimamedia thickness as measured by ultrasound. Serum adiponectin levels and the size and number of adipocytes were also measured.

Results: At baseline, mean age, proportion of female participation, race and ethnicity distribution, blood pressure, Body Mass Index (BMI) and anthropometric measures of subjects in the three groups were not statistically different. After 6 months, we observed significant decrease of intramuscular fat and significant increase of subcutaneous thigh fat in groups B and C as compared to group A. The average carotid artery intimal thickness increased in group A (p<0.01), but not in group B, and decreased in group C (p<0.01). Serum adiponectin levels rose sharply (p<0.001) in the treatment groups only. A significant positive correlation was observed between the change of the adiponectin levels and subcutaneous thigh fat. Conclusion: Results of this study supports the use of pioglitazone in the prevention of stroke and peripheral vascular disease in highrisk populations.

Keywords

Full Text

Full text is available in PDF

comments